Kiadis Pharma to present at upcoming conferences in November 2019
Amsterdam, The Netherlands, November 5, 2019 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company, today announces that the Kiadis management team will present and will host meetings at the following conferences in November 2019.
FT Global Pharmaceuticals and Biotechnology Summit
November 12, 2019, London, UK
Arthur Lahr, Chief Executive Officer, will participate in a panel discussion related to ‘Rewarding Innovation: What is the Regulation we Need?’ held on November 12th at 11:35am GMT.
There is no live webcast available.
Solebury Trout KOL Day
November 15, 2019, New York, US
Management will present on November 15th at 9:30am EST
Arthur Lahr, Chief Executive Officer, will begin with a brief corporate overview which will be followed by a presentation from Dean Lee, MD, PhD – Hematology and Oncology at Nationwide Children’s Hospital and Director of the Cellular Therapy and Cancer Immunology Program at Nationwide Children's Hospital, The Ohio State U Comprehensive Cancer Center.
A live webcast of the presentation will be available here: https://services.choruscall.com/links/kds191115.html
Stifel 2019 Healthcare Conference
November 19, 2019, New York, US
Management will present on November 19th at 4:10pm EST
A live webcast of the presentation will be available here: http://wsw.com/webcast/stifel18/kds/
Jefferies 2019 London Healthcare Conference
November 20, 2019, London, UK
Management will present on November 20th at 3:20pm GMT
A live webcast of the presentation will be available here: http://wsw.com/webcast/jeff123/kds/
An archived replay of the webcasts will be available on the Company's website for approximately 90 days following the presentation.
| Kiadis Pharma:|
Maryann Cimino, Manager, Corporate Affairs
Tel: +1 (617) 710-7305
| Optimum Strategic Communications:|
Mary Clark, Supriya Mathur, Hollie Vile
Tel: +44 203 950 9144
David Brilleslijper (Amsterdam)
Tel: +31 610 942 514
Founded in 1997, Kiadis Pharma, is a fully integrated biopharmaceutical company committed to developing innovative therapies for patients with late-stage blood cancers. With headquarters in Amsterdam, the Netherlands, and offices and activities in the US and across Europe, Kiadis Pharma is reimagining medicine by leveraging the natural strengths of humanity and our collective immune system to source the best cells for life.
Kiadis Pharma is listed on the regulated market of Euronext Amsterdam and Euronext Brussels since July 2, 2015, under the symbol KDS. Learn more at kiadis.com.
Forward Looking Statements
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect Kiadis Pharma’s or, as appropriate, Kiadis Pharma’s directors’ current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, regulation, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, Kiadis Pharma expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither Kiadis Pharma nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.